Corrigendum: Defining discriminatory antibody fingerprints in active and latent tuberculosis

Front Immunol. 2023 Nov 21:14:1329784. doi: 10.3389/fimmu.2023.1329784. eCollection 2023.

Nadege Nziza^#¹, Deniz Cizmeci^#¹, Leela Davies^{1

2}, Edward B Irvine^{1

3}, Wonyeong Jung¹, Brooke A Fenderson¹, Marwou de Kock⁴, Willem A Hanekom^{5

6}, Kees L M C Franken⁷, Cheryl L Day⁸, Tom H M Ottenhoff⁷, Galit Alter¹

¹ Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
² Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, United States.
³ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
⁴ South African Tuberculosis Vaccine Initiative (SATVI) and School of Child and Adolescent Health, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
⁵ Africa Health Research Institute, Durban, South Africa.
⁶ Division of Infection and Immunity, University College London, London, United Kingdom.
⁷ Department of Infectious Disease, Leiden University, Leiden, Netherlands.
⁸ Department of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA, United States.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.856906.].

Keywords: HIV; active and latent tuberculosis; antibodies; biomarkers; diagnostics.